RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
RedHill Biopharma (RDHL) Tops Q3 EPS by 16c
November 30, 2021 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.52 million.
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
... More